Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain was written by Ferri, Nicola;Facchetti, Giorgio;Pellegrino, Sara;Ricci, Chiara;Curigliano, Giuseppe;Pini, Elena;Rimoldi, Isabella. And the article was included in Bioorganic & Medicinal Chemistry in 2015.Product Details of 22600-77-7 This article mentions the following:
A series of imidazole based platinum(II) complexes (I–IV) were synthesized and evaluated for their cytotoxicity in HCT-116 cancer cell line, known for being partially resistant to cisplatin but sensitive to oxaliplatin. Lipophilicity was modulated by introducing differently long saturated and unsaturated chains at the N1 of the imidazole moiety. Pt-I displayed the higher cytotoxic effect achieving a IC50 = 38.0 ± 14.1 μM, comparable to the oxaliplatin value. The interaction between the imidazole platinum(II) complexes and the octapeptide called Mets7, the methionine-rich motif mimicking the N-terminal domain of the yCtr-1, was evaluated in order to have a major insight of the uptake and the eventual resistance mechanisms for the so-synthesized novel platinum compounds In the experiment, the researchers used many compounds, for example, (1H-Imidazol-2-yl)methanamine dihydrochloride (cas: 22600-77-7Product Details of 22600-77-7).
(1H-Imidazol-2-yl)methanamine dihydrochloride (cas: 22600-77-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Product Details of 22600-77-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem